

Bundamedik's DGNS (BMHS) Prints Revenue of IDR 168.8 Billion in Semester I-2021
05 July 2022
Bundamedik's DGNS (BMHS) successfully recorded a net income of Rp. 168.8 billion in the first semester of 2021 or grew 280.8% yoy
IDXChannel – The issuer of PT Diagnos Laboratorium Utama Tbk (DGNS), a clinical laboratory under the umbrella of PT Bundamedik Tbk (BMHS) posted a net income of Rp168.8 billion in the first semester of 2021 or grew 280.8% yoy.
Meanwhile, the company's net profit shot higher, growing 460.9% yoy or Rp. 46.1 billion in the first 6 months of 2021. In the period of June 30, 2021, the company also recorded cash and cash equivalents of Rp. 52.8 billion, an increase of 219. % compared to the cash position on December 31, 2020. This cash fund will be used by the company to fund capital expenditures for expansion purposes.
In semester I-2021, the company has carried out 118,865 PCR tests or Covid-19 tests or grew 713% yoy from semester I-2020 of 14,619 tests. In addition, routine tests other than PCR also grew by 79% yoy or equivalent to 255,899 routine checks from the first semester of 2020 which was only 142,850.
During the first 6 months in 2021, the company also managed to grow the number of outlets and branches of the company from 13 outlets and branches on December 31, 2020, to 24 outlets and branches. Of the 24 outlets and branches, 10 outlets are in the form of swab centers and laboratory outlets. In the near future, the company will have 32 outlets and branches to the island of Sulawesi. (Adv)
